Emergent BioSolutions | EBS - Pre Tax Profit

Stock Price
10.93
Daily Change
-0.06 -0.55%
Monthly
-4.96%
Yearly
41.76%
Q1 Forecast
10.65

Emergent BioSolutions reported $-130.8M in Pre-Tax Profit for its fiscal quarter ending in March of 2023.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 44.6M 4.38M Sep/2025
Akebia Therapeutics USD 6.11M 28.92M Mar/2025
ALKERMES USD 100.74M 4.1M Sep/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
Amarin USD -8.12M 5.34M Sep/2025
ANI Pharmaceuticals USD 49.52M 39M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Coherus Biosciences USD -47.4M 14.9M Mar/2025
Exact Sciences USD -17.76M 17.7M Sep/2025
Exelixis USD 252.69M 275K Dec/2025
Glaxosmithkline GBP 2.46B 569M Sep/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Ionis Pharmaceuticals USD -129M 253M Sep/2025
Ironwood Pharmaceuticals USD 68.02M 30.2M Sep/2025
Lexicon Pharmaceuticals USD -53.43M 5.03M Jun/2024
Lonza CHF 624M 197M Dec/2024
Merck USD 6.74B 22M Sep/2025
Moderna USD -187M 631M Sep/2025
Myriad Genetics USD 6.2M 2.1M Dec/2024
Nektar Therapeutics USD -37.05M 15.27M Sep/2024
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Pacira USD -1.93M 10.63M Jun/2025
Pfizer USD 3.33B 290M Sep/2025
PTC Therapeutics USD -139.08M 116.01M Dec/2025
Sanofi EUR -1.16B 5.5B Dec/2025
Sarepta Therapeutics USD -194.05M 347.69M Sep/2025
United Therapeutics USD 438M 29.6M Sep/2025
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024
Xoma USD 15.98M 24.58M Jun/2024